Compare AXS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXS | BLTE |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Bermuda | United States |
| Employees | 1966 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.2B |
| IPO Year | N/A | 2021 |
| Metric | AXS | BLTE |
|---|---|---|
| Price | $96.07 | $147.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $121.29 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 507.2K | 164.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.53 | N/A |
| Revenue Next Year | $6.95 | $492.11 |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $88.07 | $56.68 |
| 52 Week High | $110.34 | $200.00 |
| Indicator | AXS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 47.82 |
| Support Level | $94.12 | $148.00 |
| Resistance Level | $99.01 | $168.44 |
| Average True Range (ATR) | 2.28 | 8.48 |
| MACD | -0.40 | 0.62 |
| Stochastic Oscillator | 24.77 | 58.23 |
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.